Click for best price
Aflibercept Biosimilars Market Size, Share 2023
Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It is an inhibitor of vascular endothelial growth factor (VEGF).
This report aims to provide a comprehensive presentation of the global market for Aflibercept Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Aflibercept Biosimilars. This report contains market size and forecasts of Aflibercept Biosimilars in global, including the following market information:
Global Aflibercept Biosimilars Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Aflibercept Biosimilars Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Aflibercept Biosimilars companies in 2022 (%)
The global Aflibercept Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Intravitreal Injection Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Aflibercept Biosimilars include Regeneron, Sanofi, Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly and Bayer, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Aflibercept Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Aflibercept Biosimilars Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Aflibercept Biosimilars Market Segment Percentages, by Type, 2022 (%)
Intravitreal Injection
Intravenous Injection
Global Aflibercept Biosimilars Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Aflibercept Biosimilars Market Segment Percentages, by Application, 2022 (%)
Wet Macular Degeneration
Metastatic Colorectal Cancer
Global Aflibercept Biosimilars Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Aflibercept Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Aflibercept Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Aflibercept Biosimilars revenues share in global market, 2022 (%)
Key companies Aflibercept Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Aflibercept Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Regeneron
Sanofi
Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Outline of Major Chapters:
Chapter 1: Introduces the definition of Aflibercept Biosimilars, market overview.
Chapter 2: Global Aflibercept Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Aflibercept Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Aflibercept Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Aflibercept Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Aflibercept Biosimilars Market, Global Outlook and Forecast 2023-2032 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
124 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Aflibercept Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Aflibercept Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Aflibercept Biosimilars Overall Market Size
2.1 Global Aflibercept Biosimilars Market Size: 2022 VS 2032
2.2 Global Aflibercept Biosimilars Revenue, Prospects & Forecasts: 2018-2032
2.3 Global Aflibercept Biosimilars Sales: 2018-2032
3 Company Landscape
3.1 Top Aflibercept Biosimilars Players in Global Market
3.2 Top Global Aflibercept Biosimilars Companies Ranked by Revenue
3.3 Global Aflibercept Biosimilars Revenue by Companies
3.4 Global Aflibercept Biosimilars Sales by Companies
3.5 Global Aflibercept Biosimilars Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Aflibercept Biosimilars Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Aflibercept Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Aflibercept Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Aflibercept Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Aflibercept Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Aflibercept Biosimilars Market Size Markets, 2022 & 2032
4.1.2 Intravitreal Injection
4.1.3 Intravenous Injection
4.2 By Type - Global Aflibercept Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Aflibercept Biosimilars Revenue, 2018-2023
4.2.2 By Type - Global Aflibercept Biosimilars Revenue, 2024-2032
4.2.3 By Type - Global Aflibercept Biosimilars Revenue Market Share, 2018-2032
4.3 By Type - Global Aflibercept Biosimilars Sales & Forecasts
4.3.1 By Type - Global Aflibercept Biosimilars Sales, 2018-2023
4.3.2 By Type - Global Aflibercept Biosimilars Sales, 2024-2032
4.3.3 By Type - Global Aflibercept Biosimilars Sales Market Share, 2018-2032
4.4 By Type - Global Aflibercept Biosimilars Price (Manufacturers Selling Prices), 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Aflibercept Biosimilars Market Size, 2022 & 2032
5.1.2 Wet Macular Degeneration
5.1.3 Metastatic Colorectal Cancer
5.2 By Application - Global Aflibercept Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Aflibercept Biosimilars Revenue, 2018-2023
5.2.2 By Application - Global Aflibercept Biosimilars Revenue, 2024-2032
5.2.3 By Application - Global Aflibercept Biosimilars Revenue Market Share, 2018-2032
5.3 By Application - Global Aflibercept Biosimilars Sales & Forecasts
5.3.1 By Application - Global Aflibercept Biosimilars Sales, 2018-2023
5.3.2 By Application - Global Aflibercept Biosimilars Sales, 2024-2032
5.3.3 By Application - Global Aflibercept Biosimilars Sales Market Share, 2018-2032
5.4 By Application - Global Aflibercept Biosimilars Price (Manufacturers Selling Prices), 2018-2032
6 Sights by Region
6.1 By Region - Global Aflibercept Biosimilars Market Size, 2022 & 2032
6.2 By Region - Global Aflibercept Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Aflibercept Biosimilars Revenue, 2018-2023
6.2.2 By Region - Global Aflibercept Biosimilars Revenue, 2024-2032
6.2.3 By Region - Global Aflibercept Biosimilars Revenue Market Share, 2018-2032
6.3 By Region - Global Aflibercept Biosimilars Sales & Forecasts
6.3.1 By Region - Global Aflibercept Biosimilars Sales, 2018-2023
6.3.2 By Region - Global Aflibercept Biosimilars Sales, 2024-2032
6.3.3 By Region - Global Aflibercept Biosimilars Sales Market Share, 2018-2032
6.4 North America
6.4.1 By Country - North America Aflibercept Biosimilars Revenue, 2018-2032
6.4.2 By Country - North America Aflibercept Biosimilars Sales, 2018-2032
6.4.3 US Aflibercept Biosimilars Market Size, 2018-2032
6.4.4 Canada Aflibercept Biosimilars Market Size, 2018-2032
6.4.5 Mexico Aflibercept Biosimilars Market Size, 2018-2032
6.5 Europe
6.5.1 By Country - Europe Aflibercept Biosimilars Revenue, 2018-2032
6.5.2 By Country - Europe Aflibercept Biosimilars Sales, 2018-2032
6.5.3 Germany Aflibercept Biosimilars Market Size, 2018-2032
6.5.4 France Aflibercept Biosimilars Market Size, 2018-2032
6.5.5 U.K. Aflibercept Biosimilars Market Size, 2018-2032
6.5.6 Italy Aflibercept Biosimilars Market Size, 2018-2032
6.5.7 Russia Aflibercept Biosimilars Market Size, 2018-2032
6.5.8 Nordic Countries Aflibercept Biosimilars Market Size, 2018-2032
6.5.9 Benelux Aflibercept Biosimilars Market Size, 2018-2032
6.6 Asia
6.6.1 By Region - Asia Aflibercept Biosimilars Revenue, 2018-2032
6.6.2 By Region - Asia Aflibercept Biosimilars Sales, 2018-2032
6.6.3 China Aflibercept Biosimilars Market Size, 2018-2032
6.6.4 Japan Aflibercept Biosimilars Market Size, 2018-2032
6.6.5 South Korea Aflibercept Biosimilars Market Size, 2018-2032
6.6.6 Southeast Asia Aflibercept Biosimilars Market Size, 2018-2032
6.6.7 India Aflibercept Biosimilars Market Size, 2018-2032
6.7 South America
6.7.1 By Country - South America Aflibercept Biosimilars Revenue, 2018-2032
6.7.2 By Country - South America Aflibercept Biosimilars Sales, 2018-2032
6.7.3 Brazil Aflibercept Biosimilars Market Size, 2018-2032
6.7.4 Argentina Aflibercept Biosimilars Market Size, 2018-2032
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Aflibercept Biosimilars Revenue, 2018-2032
6.8.2 By Country - Middle East & Africa Aflibercept Biosimilars Sales, 2018-2032
6.8.3 Turkey Aflibercept Biosimilars Market Size, 2018-2032
6.8.4 Israel Aflibercept Biosimilars Market Size, 2018-2032
6.8.5 Saudi Arabia Aflibercept Biosimilars Market Size, 2018-2032
6.8.6 UAE Aflibercept Biosimilars Market Size, 2018-2032
7 Manufacturers & Brands Profiles
7.1 Regeneron
7.1.1 Regeneron Company Summary
7.1.2 Regeneron Business Overview
7.1.3 Regeneron Aflibercept Biosimilars Major Product Offerings
7.1.4 Regeneron Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.1.5 Regeneron Key News & Latest Developments
7.2 Sanofi
7.2.1 Sanofi Company Summary
7.2.2 Sanofi Business Overview
7.2.3 Sanofi Aflibercept Biosimilars Major Product Offerings
7.2.4 Sanofi Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.2.5 Sanofi Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Aflibercept Biosimilars Major Product Offerings
7.3.4 Novartis Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Genentech
7.4.1 Genentech Company Summary
7.4.2 Genentech Business Overview
7.4.3 Genentech Aflibercept Biosimilars Major Product Offerings
7.4.4 Genentech Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.4.5 Genentech Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Aflibercept Biosimilars Major Product Offerings
7.5.4 Roche Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.5.5 Roche Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Aflibercept Biosimilars Major Product Offerings
7.6.4 Pfizer Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Sartorius
7.7.1 Sartorius Company Summary
7.7.2 Sartorius Business Overview
7.7.3 Sartorius Aflibercept Biosimilars Major Product Offerings
7.7.4 Sartorius Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.7.5 Sartorius Key News & Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Company Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Aflibercept Biosimilars Major Product Offerings
7.8.4 Eli Lilly Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.8.5 Eli Lilly Key News & Latest Developments
7.9 Bayer
7.9.1 Bayer Company Summary
7.9.2 Bayer Business Overview
7.9.3 Bayer Aflibercept Biosimilars Major Product Offerings
7.9.4 Bayer Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.9.5 Bayer Key News & Latest Developments
7.10 Amgen
7.10.1 Amgen Company Summary
7.10.2 Amgen Business Overview
7.10.3 Amgen Aflibercept Biosimilars Major Product Offerings
7.10.4 Amgen Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.10.5 Amgen Key News & Latest Developments
7.11 PlantForm
7.11.1 PlantForm Company Summary
7.11.2 PlantForm Aflibercept Biosimilars Business Overview
7.11.3 PlantForm Aflibercept Biosimilars Major Product Offerings
7.11.4 PlantForm Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.11.5 PlantForm Key News & Latest Developments
7.12 PharmaPraxis
7.12.1 PharmaPraxis Company Summary
7.12.2 PharmaPraxis Aflibercept Biosimilars Business Overview
7.12.3 PharmaPraxis Aflibercept Biosimilars Major Product Offerings
7.12.4 PharmaPraxis Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.12.5 PharmaPraxis Key News & Latest Developments
7.13 Samsung Bioepis
7.13.1 Samsung Bioepis Company Summary
7.13.2 Samsung Bioepis Aflibercept Biosimilars Business Overview
7.13.3 Samsung Bioepis Aflibercept Biosimilars Major Product Offerings
7.13.4 Samsung Bioepis Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.13.5 Samsung Bioepis Key News & Latest Developments
7.14 Centus
7.14.1 Centus Company Summary
7.14.2 Centus Business Overview
7.14.3 Centus Aflibercept Biosimilars Major Product Offerings
7.14.4 Centus Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.14.5 Centus Key News & Latest Developments
7.15 Cadila Pharmaceuticals
7.15.1 Cadila Pharmaceuticals Company Summary
7.15.2 Cadila Pharmaceuticals Business Overview
7.15.3 Cadila Pharmaceuticals Aflibercept Biosimilars Major Product Offerings
7.15.4 Cadila Pharmaceuticals Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.15.5 Cadila Pharmaceuticals Key News & Latest Developments
7.16 Dr Reddy's
7.16.1 Dr Reddy's Company Summary
7.16.2 Dr Reddy's Business Overview
7.16.3 Dr Reddy's Aflibercept Biosimilars Major Product Offerings
7.16.4 Dr Reddy's Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.16.5 Dr Reddy's Key News & Latest Developments
7.17 Aurobindo Pharma
7.17.1 Aurobindo Pharma Company Summary
7.17.2 Aurobindo Pharma Business Overview
7.17.3 Aurobindo Pharma Aflibercept Biosimilars Major Product Offerings
7.17.4 Aurobindo Pharma Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.17.5 Aurobindo Pharma Key News & Latest Developments
7.18 Biocad
7.18.1 Biocad Company Summary
7.18.2 Biocad Business Overview
7.18.3 Biocad Aflibercept Biosimilars Major Product Offerings
7.18.4 Biocad Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.18.5 Biocad Key News & Latest Developments
7.19 MAbxience
7.19.1 MAbxience Company Summary
7.19.2 MAbxience Business Overview
7.19.3 MAbxience Aflibercept Biosimilars Major Product Offerings
7.19.4 MAbxience Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.19.5 MAbxience Key News & Latest Developments
7.20 Hetero
7.20.1 Hetero Company Summary
7.20.2 Hetero Business Overview
7.20.3 Hetero Aflibercept Biosimilars Major Product Offerings
7.20.4 Hetero Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.20.5 Hetero Key News & Latest Developments
7.21 Biocon
7.21.1 Biocon Company Summary
7.21.2 Biocon Business Overview
7.21.3 Biocon Aflibercept Biosimilars Major Product Offerings
7.21.4 Biocon Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.21.5 Biocon Key News & Latest Developments
7.22 Kirin Biologics
7.22.1 Kirin Biologics Company Summary
7.22.2 Kirin Biologics Business Overview
7.22.3 Kirin Biologics Aflibercept Biosimilars Major Product Offerings
7.22.4 Kirin Biologics Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.22.5 Kirin Biologics Key News & Latest Developments
7.23 Mylan
7.23.1 Mylan Company Summary
7.23.2 Mylan Business Overview
7.23.3 Mylan Aflibercept Biosimilars Major Product Offerings
7.23.4 Mylan Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.23.5 Mylan Key News & Latest Developments
7.24 BeiGene
7.24.1 BeiGene Company Summary
7.24.2 BeiGene Business Overview
7.24.3 BeiGene Aflibercept Biosimilars Major Product Offerings
7.24.4 BeiGene Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.24.5 BeiGene Key News & Latest Developments
7.25 Innovent
7.25.1 Innovent Company Summary
7.25.2 Innovent Business Overview
7.25.3 Innovent Aflibercept Biosimilars Major Product Offerings
7.25.4 Innovent Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.25.5 Innovent Key News & Latest Developments
7.26 Qilu Pharmaceutical
7.26.1 Qilu Pharmaceutical Company Summary
7.26.2 Qilu Pharmaceutical Business Overview
7.26.3 Qilu Pharmaceutical Aflibercept Biosimilars Major Product Offerings
7.26.4 Qilu Pharmaceutical Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.26.5 Qilu Pharmaceutical Key News & Latest Developments
7.27 Hengrui Pharmaceuticals
7.27.1 Hengrui Pharmaceuticals Company Summary
7.27.2 Hengrui Pharmaceuticals Business Overview
7.27.3 Hengrui Pharmaceuticals Aflibercept Biosimilars Major Product Offerings
7.27.4 Hengrui Pharmaceuticals Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.27.5 Hengrui Pharmaceuticals Key News & Latest Developments
7.28 Hisun Pharmaceutical
7.28.1 Hisun Pharmaceutical Company Summary
7.28.2 Hisun Pharmaceutical Business Overview
7.28.3 Hisun Pharmaceutical Aflibercept Biosimilars Major Product Offerings
7.28.4 Hisun Pharmaceutical Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.28.5 Hisun Pharmaceutical Key News & Latest Developments
7.29 TOT BIOPHARM
7.29.1 TOT BIOPHARM Company Summary
7.29.2 TOT BIOPHARM Business Overview
7.29.3 TOT BIOPHARM Aflibercept Biosimilars Major Product Offerings
7.29.4 TOT BIOPHARM Aflibercept Biosimilars Sales and Revenue in Global (2018-2023)
7.29.5 TOT BIOPHARM Key News & Latest Developments
8 Global Aflibercept Biosimilars Production Capacity, Analysis
8.1 Global Aflibercept Biosimilars Production Capacity, 2018-2032
8.2 Aflibercept Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Aflibercept Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Aflibercept Biosimilars Supply Chain Analysis
10.1 Aflibercept Biosimilars Industry Value Chain
10.2 Aflibercept Biosimilars Upstream Market
10.3 Aflibercept Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Aflibercept Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Aflibercept Biosimilars in Global Market
Table 2. Top Aflibercept Biosimilars Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Aflibercept Biosimilars Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Aflibercept Biosimilars Revenue Share by Companies, 2018-2023
Table 5. Global Aflibercept Biosimilars Sales by Companies, (K Units), 2018-2023
Table 6. Global Aflibercept Biosimilars Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Aflibercept Biosimilars Price (2018-2023) & (K USD/Unit)
Table 8. Global Manufacturers Aflibercept Biosimilars Product Type
Table 9. List of Global Tier 1 Aflibercept Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Aflibercept Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Aflibercept Biosimilars Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Global Aflibercept Biosimilars Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Aflibercept Biosimilars Revenue (US$, Mn), 2024-2032
Table 14. By Type - Global Aflibercept Biosimilars Sales (K Units), 2018-2023
Table 15. By Type - Global Aflibercept Biosimilars Sales (K Units), 2024-2032
Table 16. By Application ? Global Aflibercept Biosimilars Revenue, (US$, Mn), 2022 & 2032
Table 17. By Application - Global Aflibercept Biosimilars Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Aflibercept Biosimilars Revenue (US$, Mn), 2024-2032
Table 19. By Application - Global Aflibercept Biosimilars Sales (K Units), 2018-2023
Table 20. By Application - Global Aflibercept Biosimilars Sales (K Units), 2024-2032
Table 21. By Region ? Global Aflibercept Biosimilars Revenue, (US$, Mn), 2022 VS 2032
Table 22. By Region - Global Aflibercept Biosimilars Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Aflibercept Biosimilars Revenue (US$, Mn), 2024-2032
Table 24. By Region - Global Aflibercept Biosimilars Sales (K Units), 2018-2023
Table 25. By Region - Global Aflibercept Biosimilars Sales (K Units), 2024-2032
Table 26. By Country - North America Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Aflibercept Biosimilars Revenue, (US$, Mn), 2024-2032
Table 28. By Country - North America Aflibercept Biosimilars Sales, (K Units), 2018-2023
Table 29. By Country - North America Aflibercept Biosimilars Sales, (K Units), 2024-2032
Table 30. By Country - Europe Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Aflibercept Biosimilars Revenue, (US$, Mn), 2024-2032
Table 32. By Country - Europe Aflibercept Biosimilars Sales, (K Units), 2018-2023
Table 33. By Country - Europe Aflibercept Biosimilars Sales, (K Units), 2024-2032
Table 34. By Region - Asia Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Aflibercept Biosimilars Revenue, (US$, Mn), 2024-2032
Table 36. By Region - Asia Aflibercept Biosimilars Sales, (K Units), 2018-2023
Table 37. By Region - Asia Aflibercept Biosimilars Sales, (K Units), 2024-2032
Table 38. By Country - South America Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Aflibercept Biosimilars Revenue, (US$, Mn), 2024-2032
Table 40. By Country - South America Aflibercept Biosimilars Sales, (K Units), 2018-2023
Table 41. By Country - South America Aflibercept Biosimilars Sales, (K Units), 2024-2032
Table 42. By Country - Middle East & Africa Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Aflibercept Biosimilars Revenue, (US$, Mn), 2024-2032
Table 44. By Country - Middle East & Africa Aflibercept Biosimilars Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Aflibercept Biosimilars Sales, (K Units), 2024-2032
Table 46. Regeneron Company Summary
Table 47. Regeneron Aflibercept Biosimilars Product Offerings
Table 48. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 49. Regeneron Key News & Latest Developments
Table 50. Sanofi Company Summary
Table 51. Sanofi Aflibercept Biosimilars Product Offerings
Table 52. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 53. Sanofi Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Aflibercept Biosimilars Product Offerings
Table 56. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. Genentech Company Summary
Table 59. Genentech Aflibercept Biosimilars Product Offerings
Table 60. Genentech Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 61. Genentech Key News & Latest Developments
Table 62. Roche Company Summary
Table 63. Roche Aflibercept Biosimilars Product Offerings
Table 64. Roche Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 65. Roche Key News & Latest Developments
Table 66. Pfizer Company Summary
Table 67. Pfizer Aflibercept Biosimilars Product Offerings
Table 68. Pfizer Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 69. Pfizer Key News & Latest Developments
Table 70. Sartorius Company Summary
Table 71. Sartorius Aflibercept Biosimilars Product Offerings
Table 72. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 73. Sartorius Key News & Latest Developments
Table 74. Eli Lilly Company Summary
Table 75. Eli Lilly Aflibercept Biosimilars Product Offerings
Table 76. Eli Lilly Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 77. Eli Lilly Key News & Latest Developments
Table 78. Bayer Company Summary
Table 79. Bayer Aflibercept Biosimilars Product Offerings
Table 80. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 81. Bayer Key News & Latest Developments
Table 82. Amgen Company Summary
Table 83. Amgen Aflibercept Biosimilars Product Offerings
Table 84. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 85. Amgen Key News & Latest Developments
Table 86. PlantForm Company Summary
Table 87. PlantForm Aflibercept Biosimilars Product Offerings
Table 88. PlantForm Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 89. PlantForm Key News & Latest Developments
Table 90. PharmaPraxis Company Summary
Table 91. PharmaPraxis Aflibercept Biosimilars Product Offerings
Table 92. PharmaPraxis Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 93. PharmaPraxis Key News & Latest Developments
Table 94. Samsung Bioepis Company Summary
Table 95. Samsung Bioepis Aflibercept Biosimilars Product Offerings
Table 96. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 97. Samsung Bioepis Key News & Latest Developments
Table 98. Centus Company Summary
Table 99. Centus Aflibercept Biosimilars Product Offerings
Table 100. Centus Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 101. Centus Key News & Latest Developments
Table 102. Cadila Pharmaceuticals Company Summary
Table 103. Cadila Pharmaceuticals Aflibercept Biosimilars Product Offerings
Table 104. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 105. Cadila Pharmaceuticals Key News & Latest Developments
Table 106. Dr Reddy's Company Summary
Table 107. Dr Reddy's Aflibercept Biosimilars Product Offerings
Table 108. Dr Reddy's Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 109. Dr Reddy's Key News & Latest Developments
Table 110. Aurobindo Pharma Company Summary
Table 111. Aurobindo Pharma Aflibercept Biosimilars Product Offerings
Table 112. Aurobindo Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 113. Aurobindo Pharma Key News & Latest Developments
Table 114. Biocad Company Summary
Table 115. Biocad Aflibercept Biosimilars Product Offerings
Table 116. Biocad Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 117. Biocad Key News & Latest Developments
Table 118. MAbxience Company Summary
Table 119. MAbxience Aflibercept Biosimilars Product Offerings
Table 120. MAbxience Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 121. MAbxience Key News & Latest Developments
Table 122. Hetero Company Summary
Table 123. Hetero Aflibercept Biosimilars Product Offerings
Table 124. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 125. Hetero Key News & Latest Developments
Table 126. Biocon Company Summary
Table 127. Biocon Aflibercept Biosimilars Product Offerings
Table 128. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 129. Biocon Key News & Latest Developments
Table 130. Kirin Biologics Company Summary
Table 131. Kirin Biologics Aflibercept Biosimilars Product Offerings
Table 132. Kirin Biologics Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 133. Kirin Biologics Key News & Latest Developments
Table 134. Mylan Company Summary
Table 135. Mylan Aflibercept Biosimilars Product Offerings
Table 136. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 137. Mylan Key News & Latest Developments
Table 138. BeiGene Company Summary
Table 139. BeiGene Aflibercept Biosimilars Product Offerings
Table 140. BeiGene Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 141. BeiGene Key News & Latest Developments
Table 142. Innovent Company Summary
Table 143. Innovent Aflibercept Biosimilars Product Offerings
Table 144. Innovent Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 145. Innovent Key News & Latest Developments
Table 146. Qilu Pharmaceutical Company Summary
Table 147. Qilu Pharmaceutical Aflibercept Biosimilars Product Offerings
Table 148. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 149. Qilu Pharmaceutical Key News & Latest Developments
Table 150. Hengrui Pharmaceuticals Company Summary
Table 151. Hengrui Pharmaceuticals Aflibercept Biosimilars Product Offerings
Table 152. Hengrui Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 153. Hengrui Pharmaceuticals Key News & Latest Developments
Table 154. Hisun Pharmaceutical Company Summary
Table 155. Hisun Pharmaceutical Aflibercept Biosimilars Product Offerings
Table 156. Hisun Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 157. Hisun Pharmaceutical Key News & Latest Developments
Table 158. TOT BIOPHARM Company Summary
Table 159. TOT BIOPHARM Aflibercept Biosimilars Product Offerings
Table 160. TOT BIOPHARM Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2018-2023)
Table 161. TOT BIOPHARM Key News & Latest Developments
Table 162. Aflibercept Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 163. Global Aflibercept Biosimilars Capacity Market Share of Key Manufacturers, 2021-2023
Table 164. Global Aflibercept Biosimilars Production by Region, 2018-2023 (K Units)
Table 165. Global Aflibercept Biosimilars Production by Region, 2024-2032 (K Units)
Table 166. Aflibercept Biosimilars Market Opportunities & Trends in Global Market
Table 167. Aflibercept Biosimilars Market Drivers in Global Market
Table 168. Aflibercept Biosimilars Market Restraints in Global Market
Table 169. Aflibercept Biosimilars Raw Materials
Table 170. Aflibercept Biosimilars Raw Materials Suppliers in Global Market
Table 171. Typical Aflibercept Biosimilars Downstream
Table 172. Aflibercept Biosimilars Downstream Clients in Global Market
Table 173. Aflibercept Biosimilars Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Aflibercept Biosimilars Segment by Type in 2022
Figure 2. Aflibercept Biosimilars Segment by Application in 2022
Figure 3. Global Aflibercept Biosimilars Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Aflibercept Biosimilars Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Aflibercept Biosimilars Revenue, 2018-2032 (US$, Mn)
Figure 7. Aflibercept Biosimilars Sales in Global Market: 2018-2032 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Aflibercept Biosimilars Revenue in 2022
Figure 9. By Type - Global Aflibercept Biosimilars Revenue, (US$, Mn), 2022 & 2032
Figure 10. By Type - Global Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 11. By Type - Global Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 12. By Type - Global Aflibercept Biosimilars Price (K USD/Unit), 2018-2032
Figure 13. By Application - Global Aflibercept Biosimilars Revenue, (US$, Mn), 2022 & 2032
Figure 14. By Application - Global Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 15. By Application - Global Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 16. By Application - Global Aflibercept Biosimilars Price (K USD/Unit), 2018-2032
Figure 17. By Region - Global Aflibercept Biosimilars Revenue, (US$, Mn), 2022 & 2032
Figure 18. By Region - Global Aflibercept Biosimilars Revenue Market Share, 2018 VS 2022 VS 2032
Figure 19. By Region - Global Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 20. By Region - Global Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 21. By Country - North America Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 22. By Country - North America Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 23. US Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 24. Canada Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 25. Mexico Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 26. By Country - Europe Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 27. By Country - Europe Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 28. Germany Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 29. France Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 30. U.K. Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 31. Italy Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 32. Russia Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 33. Nordic Countries Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 34. Benelux Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 35. By Region - Asia Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 36. By Region - Asia Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 37. China Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 38. Japan Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 39. South Korea Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 40. Southeast Asia Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 41. India Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 42. By Country - South America Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 43. By Country - South America Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 44. Brazil Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 45. Argentina Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 46. By Country - Middle East & Africa Aflibercept Biosimilars Revenue Market Share, 2018-2032
Figure 47. By Country - Middle East & Africa Aflibercept Biosimilars Sales Market Share, 2018-2032
Figure 48. Turkey Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 49. Israel Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 50. Saudi Arabia Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 51. UAE Aflibercept Biosimilars Revenue, (US$, Mn), 2018-2032
Figure 52. Global Aflibercept Biosimilars Production Capacity (K Units), 2018-2032
Figure 53. The Percentage of Production Aflibercept Biosimilars by Region, 2022 VS 2032
Figure 54. Aflibercept Biosimilars Industry Value Chain
Figure 55. Marketing Channels
